BLA 761235 · Genentech INC
Vabysmo
Faricimab-Svoa · Intravitreal
NovelPriority reviewCDER novel approval, Jan 28, 2022: To treat neovascular (wet) aged-related macular degeneration and diabetic macular edema
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jan 28, 2022
Approved uses
4
Original approval plus efficacy supplements
Registered trials
47
16 Phase 3, 15 recruiting
FAERS reports
8,868
4,784 serious, 513 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 15, 2026.
VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with: VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.3 ) 1.1 Neovascular (wet) Age-Related Macular Degeneration (nAMD) 1.2 Diabetic Macular Edema (DME) 1.3 Macular Edema Following Retinal Vein Occlusion (RVO)
Mechanism: Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD, DME, and RVO. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD, DME, and RVO has yet to be established.
Therapeutic areas: Cardiovascular and metabolic · Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 9, 2026 Supplement 8 · Efficacy LetterLabel
- Oct 26, 2023 Supplement 3 · Efficacy LetterLabel
- Jan 27, 2023 Supplement 1 · Efficacy LabelLetter
- Jan 28, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- VABYSMO · FARICIMAB-SVOA 120MG/ML · INJECTABLE, INTRAVITREAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Faricimab" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular EdemaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04432831 · 1,479 participants · Start Aug 5, 2020 · Primary completion Oct 11, 2023
Drug: Faricimab · For: Diabetic Macular Edema
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 320 sites in all
- A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular DegenerationPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04777201 · 1,036 participants · Start Apr 19, 2021 · Primary completion Sep 3, 2024
Drug: Faricimab; Anti-VEGF Therapy · For: Neovascular Age-related Macular Degeneration
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 251 sites in all
- A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular EdemaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03622593 · 951 participants · Start Oct 9, 2018 · Primary completion Oct 19, 2020
Drug: Aflibercept; Faricimab · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Springdale, Arkansas; Bakersfield, California · 188 sites in all
- A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03622580 · 940 participants · Start Sep 5, 2018 · Primary completion Oct 20, 2020
Drug: Aflibercept; Faricimab · For: Diabetic Macular Edema
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 185 sites in all
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein OcclusionPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04740931 · 729 participants · Start Mar 2, 2021 · Primary completion Aug 9, 2022
Drug: Faricimab; Aflibercept · For: Macular Edema; Central Retinal Vein Occlusion; Hemiretinal Vein Occlusion
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 194 sites in all
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03823287 · 671 participants · Start Feb 19, 2019 · Primary completion Oct 26, 2020
Drug: Faricimab; Aflibercept · For: Wet Macular Degeneration
Sites: Phoenix, Arizona; Tucson, Arizona; Campbell, California · 161 sites in all
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03823300 · 658 participants · Start Mar 11, 2019 · Primary completion Oct 5, 2020
Drug: Faricimab; Aflibercept · For: Wet Macular Degeneration
Sites: Phoenix, Arizona; Mountain View, California; Sacramento, California · 137 sites in all
- Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMDPivotal-lookingActive, not recruiting
Jaeb Center for Health ResearchAcademic, hospital or other
NCT05904028 · 603 participants · Start Nov 9, 2023 · Primary completion Jul 30, 2027
Drug: Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule · For: Neovascular Age-related Macular Degeneration
Sites: Glendale, California; Loma Linda, California; Oakland, California · 64 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,963
- no adverse event1,970
- retinal thickening1,471
- visual impairment856
- optical coherence tomography abnormal776
- death466
- drug ineffective380
- eye inflammation360
- uveitis353
- visual acuity tests abnormal346
- visual acuity reduced332
- blindness275
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 10 |
| 2022 | 254 |
| 2023 | 771 |
| 2024 | 3,756 |
| 2025 | 1,735 |
| 2026 | 2,338 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vabysmo (Faricimab-Svoa)
2024 spending
$23.6M
Beneficiaries
2,074
8,421 claims
Per beneficiary
$11,395
$44,393.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $3,254,757 |
| 2023 | $14,996,148 |
| 2024 | $23,633,074 |
Part B: Vabysmo (Faricimab-Svoa) · HCPCS J2777
2024 spending
$1.92B
Beneficiaries
172,503
792,936 claims
Per beneficiary
$11,120
2024 ASP limit $35.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $169,912,032 |
| 2023 | $1,296,917,273 |
| 2024 | $1,918,151,107 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, et al. · Ophthalmology 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, et al. · Ophthalmology 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, et al. · Lancet 2022 · Clinical Trial, Phase III, Equivalence Trial
- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, et al. · Lancet 2022 · Clinical Trial, Phase III, Equivalence Trial
- Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials.
Chen KY, Chan HC, Chan CM · Surv Ophthalmol 2025 · Network Meta-Analysis, Systematic Review
- Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials.
Tadayoni R, Paris LP, Danzig CJ, et al. · Ophthalmology 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.